Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
97
-
Total 13F shares, excl. options
-
31,877,280
-
Shares change
-
+749,165
-
Total reported value, excl. options
-
$641,628,318
-
Value change
-
+$12,346,028
-
Put/Call ratio
-
54%
-
Number of buys
-
41
-
Number of sells
-
-48
-
Price
-
$20.13
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q4 2018
122 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2018.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 97 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31,877,280 shares
of 104,661,494 outstanding shares and own 30% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (4,311,344 shares), JPMORGAN CHASE & CO (3,805,039 shares), BlackRock Inc. (3,206,600 shares), FRANKLIN RESOURCES INC (2,975,844 shares), Bank of New York Mellon Corp (2,542,242 shares), ArrowMark Colorado Holdings LLC (2,310,903 shares), Vanguard Group Inc (1,744,357 shares), ALLIANCEBERNSTEIN L.P. (1,561,192 shares), NovaQuest Capital Management, L.L.C. (1,558,426 shares), and Capital World Investors (1,225,000 shares).
This table shows the top 97 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.